Oncology and Hematology - Prova Education

33-48 of 219

ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
MinuteCE®
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Erica L. Mayer, MD, MPH
0.50 program credits
- Erica L. Mayer, MD, MPH
0.50 program credits
MinuteCE®
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH
0.50 credits 4 episodes
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 credits 4 episodes
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD
- Tiffany Traina, MD
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
- Sara A. Hurvitz, MD, FACP
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Oncology and Hematology
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
- Sara A. Hurvitz, MD, FACP
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
MinuteCE®
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
Jennifer Johnson, MD, PhD
0.50 program credits
- Jennifer Johnson, MD, PhD
0.50 program credits
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
MinuteCE®
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
Adam J. Luginbuhl, MD; Jennifer Johnson, MD, PhD
0.50 program credits
- Adam J. Luginbuhl, MD
- Jennifer Johnson, MD, PhD
0.50 program credits
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
MinuteCE®
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
Jennifer Johnson, MD, PhD
0.50 program credits
- Jennifer Johnson, MD, PhD
0.50 program credits
MinuteCE®
Talking Through Treatment: Patient–Clinician Dialogue on Perioperative Immunotherapy in Locally Advanced HNSCC
Jennifer Johnson, MD, PhD; Adam J. Luginbuhl, MD
0.50 credits 5 episodes
- Jennifer Johnson, MD, PhD
- Adam J. Luginbuhl, MD
0.50 credits 5 episodes
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
MinuteCE®
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Adam J. Luginbuhl, MD
0.50 program credits
- Adam J. Luginbuhl, MD
0.50 program credits
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
MinuteCE®
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
Adam J. Luginbuhl, MD
0.50 program credits
- Adam J. Luginbuhl, MD
0.50 program credits
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
CME/CE
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
Neeraj Agarwal, MD, FASCO; Rana McKay, MD
0.25 credits
- Neeraj Agarwal, MD, FASCO
- Rana McKay, MD
0.25 credits
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
CME/CE
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Enriqueta Felip, MD; Kristi Orbaugh, MSN, RNP, AOCN
0.25 credits
- Enriqueta Felip, MD
- Kristi Orbaugh, MSN, RNP, AOCN
0.25 credits
The Future of HNSCC: Aligning Teams, Transforming Care
The Future of HNSCC: Aligning Teams, Transforming Care
CME/CE
The Future of HNSCC: Aligning Teams, Transforming Care
Ravindra Uppaluri, MD, PhD; Nancy Lee, MD, FASTRO
0.25 credits
- Ravindra Uppaluri, MD, PhD
- Nancy Lee, MD, FASTRO
0.25 credits

3/8